Roche News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.03.22	Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer (GlobeNewswire)
25.03.22	CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
25.03.22	Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting (GlobeNewswire)
23.03.22	Roche donates additional medicines and diagnostics for Ukraine (GlobeNewswire)
16.03.22	Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern (GlobeNewswire)
16.03.22	New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA) (GlobeNewswire)
15.03.22	Roche Annual General Meeting 2022 (GlobeNewswire)
15.03.22	Roche Generalversammlung 2022 (GlobeNewswire)
08.03.22	Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio (GlobeNewswire)
02.03.22	Roche announces donation of essential medicines to Ukraine (GlobeNewswire)
11.02.22	WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 (GlobeNewswire)
11.02.22	New two-year data for Roche’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss (GlobeNewswire)
03.02.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Jahresergebnis 2021 (GlobeNewswire)
03.02.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021 (GlobeNewswire)
01.02.22	Changes to the Roche Board of Directors and the Corporate Executive Committee (GlobeNewswire)
01.02.22	Wechsel im Verwaltungsrat und in der Konzernleitung von Roche (GlobeNewswire)
31.01.22	FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss (GlobeNewswire)
25.01.22	Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA) (GlobeNewswire)
24.01.22	The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months (GlobeNewswire)
12.01.22	Roche launches the cobas® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care (GlobeNewswire)
11.01.22	Roche introduces cobas infinity edge, a new open digital ecosystem for point of care professionals, driving improved patient outcomes and operational efficiencies in healthcare (GlobeNewswire)
24.12.21	Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States (GlobeNewswire)
14.12.21	Roche’s Polivy combination reduced the risk of disease worsening or death by 27% in people with previously untreated aggressive form of lymphoma (GlobeNewswire)
13.12.21	Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine (GlobeNewswire)
13.12.21	Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A (GlobeNewswire)
11.12.21	Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab (GlobeNewswire)
10.12.21	New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq (GlobeNewswire)
07.12.21	Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19 (GlobeNewswire)
06.12.21	Roche completed the repurchase of Roche shares from Novartis (GlobeNewswire)
06.12.21	Roche hat Rückkauf der Roche-Aktien von Novartis vollzogen (GlobeNewswire)
06.12.21	CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19 (GlobeNewswire)
06.12.21	Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections (GlobeNewswire)
03.12.21	Änderungen im Verwaltungsrat von Roche (GlobeNewswire)
03.12.21	Changes in the Board of Directors (GlobeNewswire)
03.12.21	Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant (GlobeNewswire)
01.12.21	Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases (GlobeNewswire)
26.11.21	Roche ausserordentliche Generalversammlung 2021 (GlobeNewswire)
26.11.21	Roche Extraordinary General Meeting 2021 (GlobeNewswire)
23.11.21	Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders (GlobeNewswire)
19.11.21	European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer (GlobeNewswire)
18.11.21	Roche launches cobas 5800, a new molecular diagnostics system to expand access to testing and improve patient care (GlobeNewswire)
15.11.21	Roche zum dreizehnten Mal in Folge als eines der drei nachhaltigsten Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
15.11.21	Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running (GlobeNewswire)
12.11.21	Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (GlobeNewswire)
11.11.21	CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (GlobeNewswire)
04.11.21	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche kündigt den Rückkauf der Beteiligung von Novartis an Roche an (GlobeNewswire)
04.11.21	[Ad hoc announcement pursuant to Art. 53 LR] Roche announces the repurchase of the equity stake held by Novartis in Roche (GlobeNewswire)
29.10.21	IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer (GlobeNewswire)
25.10.21	Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research (GlobeNewswire)
22.10.21	FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD) (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus
22.11.24		Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen
22.11.24		Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone
22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester

22.11.24

Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen

22.11.24

Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün